ACR Convergence 2026 Archives - ACR Meeting Abstracts

Abstract Number: 1456

RA-Associated IgA Autoantibodies (RF-IgA, Anti-RA33 IgA, Anti-PAD4 IgA) Demonstrate a Graded Association with Interstitial Lung Disease in a Real-World Autoimmune Testing Cohort
Abstract Number: 0775

Racial and Ethnic Disparities in Sepsis Outcomes Among Hospitalized Patients with Polymyositis: A National Inpatient Sample Analysis
Abstract Number: 1711

Racial and Social Disparities in Inpatient Outcomes Among Adults with SLE: A Nationwide Analysis, 2016-2023
Abstract Number: 0333

Racial Differences in Disease Activity in Systemic Lupus Erythematosus: A Longitudinal Cohort Study
Abstract Number: 1806

Racial, Sex, and Geographic Disparities in Metabolic Comorbidity-Associated Mortality Among Individuals With Systemic Autoimmune Diseases in the United States, 2018-2024
Abstract Number: 1698

Radiographic Activity Index and Total Lesion Count of MRI Score Showed Sensitivity to Change of Clinical Status in Children with Chronic Nonbacterial Osteomyelitis
Abstract Number: 1601

Radiographic Outcomes by SSA Status and Antisynthetase Subtype in Treatment-Naive IIM-ILD
Abstract Number: 2699

Radiographic Severity Influences Intra-Articular Therapeutic Strategies in Osteoarthritis: A Real-World Analysis of 832 Procedures
Abstract Number: 2533

Ramadan Fasting, Medication Practices, and Educational Needs Among Patients with Rheumatic Diseases: A Large Cross-sectional Survey
Abstract Number: 2935

Rapid and deep clinical responses to HLX79 (E-602), a first-in-class human sialidase-Fc fusion protein, plus HLX01, a rituximab biosimilar, in patients with membranous nephropathy: a Ph2 trial
Abstract Number: 2407

Rapid Remission in Rheumatoid Arthritis: A Head-to-Head Comparison of Tofacitinib and Upadacitinib
Abstract Number: 2140

Rapidly Progressive Glomerulonephritis with IgG4-Positive Plasma Cell Tubulointerstitial Infiltrate in ANCA-associated vasculitis
Abstract Number: 2846

Rare Variant Burden and Longitudinal Outcomes in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 2077

Rare Variant Phenome-Wide Association Studies Recapitulate Inborn Errors of Immunity Phenotypes in Population Biobanks
Abstract Number: 2447

RAStorm: A Foundation Model for Dynamic Comorbidity Forecasting in Rheumatoid Arthritis
Abstract Number: 2639

Rationale, Design, and Initial RA Results in Basket Registry Evaluating Umbilical Lining Stem Cells in Autoimmunity
Abstract Number: 0692

Raynaud’s Phenomenon Is an Underrecognized Manifestation of Acromegaly: Results from an International Patient Survey
Abstract Number: 1046

Reactive Aldehyde Species and Malondialdehyde-Acetaldehyde as Potential Mediators of Myocardial Dysfunction in Rheumatoid Arthritis
Abstract Number: 0914

Reactive Aldehyde Species Inhibitor ADX-246 Attenuates Autoantigen Expression and Tissue Fibrosis in a Pre-Clinical Model of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 2040

Reactive Aldehyde Species Inhibitors Attenuate the Formation of Malondialdehyde-Acetaldehyde (MAA)-Modified Proteins and Inhibits the Release of IL-6
Abstract Number: 1283

Readmission Burden and Healthcare Utilization in Lupus Nephritis: A Nationwide Readmissions Database Analysis
Abstract Number: 0583

Ready or Not? Boosting Transition Readiness in Pediatric Rheumatology
Abstract Number: 1524

REAJI Study: Predictors of Relapse During Tapering or Discontinuation of Targeted Therapies in Juvenile Idiopathic Arthritis
Abstract Number: 1325

Real World Comparative Effectiveness of Upadacitinib vs. IL-17i in Patients With Psoriatic Arthritis Previously Treated With TNF Inhibitors: Data From the OM1 Registry
Abstract Number: 0463

Real World Data on the Comparative Risk of Infections in Patients with Rheumatoid Arthritis Treated with Methotrexate versus Biologic DMARDs
Abstract Number: 0371

Real World Determinants of treatment response in Psoriatic Arthritis in a real-world cohort
Abstract Number: 0184

Real World Effectiveness and Safety of Upadacitinib in Giant Cell Arteritis
Abstract Number: 1418

Real World Evidence From the US Veterans Affairs Healthcare System of a Successful Switch to Biosimilar adalimumab-bwwd (Hadlima) from Originator adalimumab (Humira) Following a Formulary Change
Abstract Number: 1791

Real World Treatment Patterns among Patients with Dermatomyositis and Polymyositis: A US Claims-based Study
Abstract Number: 1729

Real-World Assessment of Anakinra Use in United States Inpatient Settings
Abstract Number: 0853

Real-World Attainment of Gout Remission Following Pegloticase Initiation in a U.S. Practice Based Rheumatology Network
Abstract Number: 2662

Real-World Capture of Pediatric Lupus Disease Assessments Using an EHR-Based Structured Data Collection Tool: Baseline Utilization Analysis
Abstract Number: 2929

Real-World Cardiovascular and Mortality Outcomes of Janus Kinase Inhibitors Versus Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis
Abstract Number: 2730

Real-World Clinical and Economic Burden, and Treatment Patterns of Sjögren’s Disease in Medicare Fee-For-Service Beneficiaries
Abstract Number: 2120

Real-World Clinical Burden and Longitudinal Outcomes of IgG4-Related Disease: A Large-Scale Federated Health Network Analysis
Abstract Number: 1356

Real-World Comparative Effectiveness of Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors on Skin Symptoms in Patients With Psoriatic Arthritis
Abstract Number: 2304

Real-World Comparative Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with Biologics Versus JAK Inhibitors in Psoriatic Arthritis
Abstract Number: 1730

Real-World Economic Burden of Patients with Systemic Autoimmune Rheumatic Disease-associated Interstitial Lung Disease Following ILD Progression in the United States: Retrospective, Observational, Claims Database Analysis
Abstract Number: 1237

Real-World Effectiveness and Safety of Anifrolumab Therapy: A Multicenter Collaboration
Abstract Number: 1164

Real-World Effectiveness and Safety of Avacopan in ANCA-Associated Vasculitis: A Target Trial Emulation
Abstract Number: 2141

Real-World Effectiveness and Safety of Avacopan in Granulomatosis with Polyangiitis and Microscopic Polyangiitis Over Two Years in a Large US Healthcare System
Abstract Number: 0854

Real-World Effectiveness and Safety of Janus Kinase Inhibitors in Inflammatory Arthritis: A Retrospective Cohort Study from a Tertiary Care Center in Saudi Arabia
Abstract Number: 2220

Real-world Effectiveness of Anifrolumab in Adults with SLE: A 3-Month Interim Analysis of a Multinational Prospective Observational Cohort
Abstract Number: 0693

Real-world effectiveness of Bimekizumab in refractory uveitis associated with spondyloarthritis: a multicenter study
Abstract Number: 0694

Real-World Effectiveness of Ravulizumab in C5 Inhibitor-Naïve Patients with Atypical Haemolytic Uremic Syndrome Associated with an Autoimmune Trigger
Abstract Number: 1326

Real-World Effectiveness of Risankizumab in Patients With Psoriatic Arthritis: 6-Month Interim Results From the Observational PErsistence With RISankizumab (PERIS) Study
Abstract Number: 1419

Real-World Effectiveness of Upadacitinib in Rheumatoid Arthritis: 24-Month Integrated Results From the UPHOLD and CLOSE-UP Post-Marketing Observational Studies
Abstract Number: 2142

Real-World Effectiveness, Safety, and Discontinuation of Avacopan in ANCA-Associated Vasculitis: A Systematic Review and Meta-Analysis
Abstract Number: 2143

Real-World Efficacy of Mepolizumab as First-Line Therapy for eosinophilic granulomatosis with polyangiitis (EGPA): A Retrospective Cohort study by the European EGPA Study Group
Abstract Number: 1165

Real-World Evaluation of Hepatotoxicity in Avacopan-Treated Patients with ANCA-Associated Vasculitis: A Post-Marketing Safety Study
Abstract Number: 0185

Real-world Evidence on the Steroid Sparing Effects of IL-6Ri Therapy in PMR Patients and Reduction of Glucocorticoid-Associated Adverse Events
Abstract Number: 2900

Real-World Evidence on the Use of Statins in Patients With Rheumatoid Arthritis at Increased Risk for Cardiovascular Disease
Abstract Number: 0399

Real-World Evidence Supporting Ultrasound-Based Phenotyping in Psoriatic Arthritis for therapy selection
Abstract Number: 1166

Real-World Experience with Avacopan in ANCA-Associated Vasculitis: Renal Outcomes
Abstract Number: 1238

Real-World Glucocorticoid Treatment Patterns and Utilization in Adults with SLE: A Global Systematic Literature Review
Abstract Number: 0277

Real-World Impact of Anifrolumab in Systemic Lupus Erythematosus: Insights from a Nationwide Spanish Multicenter Registry
Abstract Number: 0464

Real-World Long-Term Treatment Retention Across First- and Second-Line Advanced Therapies in Early RA: A Prospective Cohort Study
Abstract Number: 2345

Real-World Multinational Data on Fertility and Pregnancy Outcomes in Axial Spondyloarthritis: First Large-Scale Evidence from the Arab World
Abstract Number: 2305

Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients With Psoriatic Arthritis: Comparison of Guselkumab Versus Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Abstract Number: 0278

Real-world Outcomes in Systemic Lupus Erythematosus Patients Treated with Anifrolumab in Spain
Abstract Number: 2534

Real-World Patient Experiences with Concomitant Ixekizumab and Tirzepatide in Psoriatic Arthritis: Patients Recruited from the Zepbound® Savings for Taltz® US Customer Support Program
Abstract Number: 2535

Real-World Patient Perspectives on Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): Treatment Satisfaction, Quality of Life Benefits, and the Continuing Burden of Injections
Abstract Number: 2920

Real-World Patterns of Pre-Rituximab Immunoglobulin Testing, Hypogammaglobulinemia, and Immunoglobulin Replacement Therapy in Rheumatologic Diseases: A Multisite Retrospective Study
Abstract Number: 2346

Real-World Performance of the Revised ASAS-SPARTAN Criteria in Patients With Back Pain Evaluated in a Rheumatology Unit
Abstract Number: 0629

Real-World Romosozumab Utilization Patterns Among Medicare Beneficiaries: A Multistate Analysis
Abstract Number: 2953

Real-World Safety and Efficacy of Romosozumab in Severe Postmenopausal Osteoporosis: A Single-Centre Experience
Abstract Number: 2448

Real-World Safety and Retention of Tofacitinib in Elderly versus Non-Elderly Patients With Rheumatoid Arthritis: A Retrospective Cohort Study in Taiwan
Abstract Number: 0465

Real-world safety of baricitinib in rheumatoid arthritis: Incidence and predictors of herpes zoster and cardiovascular events
Abstract Number: 2899

Real-world safety of concomitant colchicine and statin therapy
Abstract Number: 1731

Real-World Sarilumab Prescribing Patterns for Polymyalgia Rheumatica in the United States Three Years After FDA Approval
Abstract Number: 1284

Real-World SLE Trajectories After Immunosuppressants: Flares, Organ Damage, and Limited Treatment Escalation
Abstract Number: 0466

Real-world therapeutic maintenance, effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis before and after PRAC recommendations
Abstract Number: 1327

Real-World Treatment Discontinuation of Risankizumab Versus IL-17 Inhibitors in Japanese Patients With Psoriatic Arthritis
Abstract Number: 2144

Real-World Treatment Patterns in Patients with Severe ANCA-Associated Vasculitis: a Longitudinal US Claim Analysis
Abstract Number: 0695

Real-world Use and Safety of a Chikungunya Virus Virus-like Particle Vaccine
Abstract Number: 2653

Real-World Use of Immunomodulation Co-therapy Among Pegloticase New Users
Abstract Number: 1732

Real‑World Treatment Landscape of Systemic Lupus Erythematosus (SLE) in the United States Among Patients Treated With Glucocorticoids and Multiple Immunosuppressive Therapies
Abstract Number: 2271

Reappraising Systemic Lupus Erythematosus-Associated Interstitial Lung Disease: Not as benign as expected
Abstract Number: 1488

Reasoning Through Uncertainty: Learning-by-Concordance in Preclinical Rheumatology Education
Abstract Number: 2306

Reasons for Treatment Discontinuation and Adverse Event Patterns in a Two-Decade Spondyloarthritis Biologic Registry
Abstract Number: 1995

Reciprocal T Cell Activation Governs Extrafollicular B Cell Differentiation and Immune Reset After CD19-CAR-T Cell Therapy in Systemic Lupus Erythematosus
Abstract Number: 2669

Recombinant Zoster Vaccine Protects Against Both Herpes Zoster and COVID-19 Infection in SLE Patients on Anifrolumab
Abstract Number: 0434

Recurrent Parotitis Is Associated with Enhanced Diagnostic Prediction in Childhood Sjögren Disease
Abstract Number: 1759

Redlining’s Enduring Impact: Linking Historic Development Policy to Missed Appointments and Health Outcomes in Rheumatology
Abstract Number: 2221

Reduced Glucocorticoid Use in Patients With SLE Receiving Intravenous/Subcutaneous Anifrolumab Versus Placebo: Pooled Data From Phase 3 Clinical Trials
Abstract Number: 2185

Reduced Heart Rate Variability Links To Subclinical Atherosclerosis in Systemic Sclerosis and Idiopathic Inflammatory Myopathies
Abstract Number: 2347

Reduced Sensitivity of the 2025 ASAS-SPARTAN Classification Criteria in Recent Axial Spondyloarthritis: Data from the DESIR Cohort
Abstract Number: 1357

Reduced Visual Photosensitivity Thresholds Are Associated With Nociplastic Pain Features in Axial Spondyloarthritis
Abstract Number: 0962

Reducing Ischemic Risk in Giant Cell Arteritis: A Meta-Analysis Assessing the Role of Aspirin
Abstract Number: 0087

Reduction of Emergency Myelopoiesis Represents a Mechanism of Action of TNF Blockade and IL-6 Deficiency in an Arthritis Model
Abstract Number: 0719

Reevaluating Febuxostat’s Cardiovascular Black Box Warning: Comparative Safety Versus Allopurinol in a Large U.S. Gout Cohort.
Abstract Number: 2600

Refractory Disease and Therapeutic Escalation in Idiopathic Inflammatory Myopathies: Differences Across Clinical Subtypes from a 25-Year Real-World experience
Abstract Number: 0908

Reframing Strength: Superwoman Schema and Self-Management in Black Women with Systemic Lupus Erythematosus
Abstract Number: 1792

Regional Differences in Demographics, Socioeconomic Characteristics, Comorbidities, and Advanced Therapy Utilization Among Patients With Rheumatic Diseases in a Large Multi-Regional U.S. Cohort
Abstract Number: 1034

Regulatory Role of IL-32γ in pathogenesis of psoriatic arthritis: A New Therapeutic Target
Abstract Number: 2791

Relapse burden and associated healthcare resource utilization in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA): A retrospective United States claims analysis
Abstract Number: 2121

Relapse Patterns and Clinical Associations in Polyarteritis Nodosa: A Retrospective Cohort Study at a U.S. Tertiary Care Center
Abstract Number: 1144

Relapsing Polychondritis Overlapping Cogan’s Syndrome: Phenotype and Outcomes in 153 Patients
Abstract Number: 1457

Relationship Between Anti-CarP Antibodies and Estimated Cardiovascular Risk in Patients with Rheumatoid Arthritis
Abstract Number: 2508

Relationship Between Anti‑TNF Drug Levels, Anti‑Drug Antibodies, and Disease Activity in Uveitis With or Without JIA: A Single-Center Descriptive Study
Abstract Number: 2272

Relationship Between Disease Activity, Organ Damage, and Functional Status in Systemic Lupus Erythematosus: Insights for Treat to Target Implementation in a Spanish Single Center Cohort
Abstract Number: 0279

Relationship Between IgG Levels and Infection Rates in Nipocalimab Treated Participants With Systemic Lupus Erythematosus (SLE) in the Phase 2 JASMINE-SLE Study
Abstract Number: 2601

Relationship between Pain Intensity and Imaging Derived Muscle and Fascia Characteristics in Patients with Inflammatory Myopathies
Abstract Number: 1167

Reliability and Content Validity of a Definition of Severe Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Abstract Number: 0526

Reliability and Validity of Sociodemographic Data from the Electronic Health Records of Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Participants
Abstract Number: 1168

Remission and Glucocorticoid Sparing With Mepolizumab and Benralizumab in Eosinophilic Granulomatosis With Polyangiitis: A Systematic Review of Randomized and Real-World Evidence.
Abstract Number: 2222

Remission and Lupus Low Disease Activity State Attainment and Glucocorticoid Reduction without Increasing Flares with Anifrolumab in Asian patients with Systemic Lupus Erythematosus: A Post Hoc Analysis from a Phase III Study
Abstract Number: 0186

Remission GCA Study – A Two Center Prospective 72 Week Follow Up Study After Standard Tocilizumab Withdrawal In Patients With Giant Cell Arteritis In Imaging Proven Remission
Abstract Number: 0888

Remodeling of the Cellular and Molecular Immune Landscape in Lymph Nodes Following CD19 CAR T-Cell Therapy
Abstract Number: 0334

Renal Histopathological Patterns in Lupus Nephritis: A Single-Center Cohort Study.
Abstract Number: 0335

Renal Response Metrics as Predictors of Subsequent Kidney Outcomes in Patients with Membranoproliferative Lupus Nephritis
Abstract Number: 1285

Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis: a two-center study.
Abstract Number: 1286

Repeat Kidney Biopsy as a Window into Tubulointerstitial Disease Progression in Lupus Nephritis: A Longitudinal Subgroup Analysis
Abstract Number: 2408

Representativeness of a U.S. biomarker discovery cohort compared to real-world data from enrolling U.S. rheumatology practices: application of target trial emulation approaches to augment longitudinal data and construct external synthetic comparator cohorts
Abstract Number: 1760

Representativeness of Youths with Pediatric Rheumatic Diseases Enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry at Six United States Medical Centers
Abstract Number: 0538

Reproductive Health and Contraceptive Counseling Among Saudi Women With Rheumatic Diseases: A Cross-Sectional Study
Abstract Number: 0539

Reproductive Health in Systemic Lupus Erythematosus: A Content and Thematic Analysis of Videos Shared on TikTok
Abstract Number: 1420

Residual Disease Burden and Barriers to Targeted Therapy Escalation in csDMARD-Treated Rheumatoid Arthritis: A European Real-World Study
Abstract Number: 0502

Residual Inflammatory Burden Is Independently Associated With Carotid Plaque Despite LDL Control and Low Disease Activity in Rheumatoid Arthritis
Abstract Number: 0585

Resilience-Oriented Functional Assessment in Adolescents with Systemic Lupus Erythematosus: A Cross-sectional Study Using Generic HRQOL Tools
Abstract Number: 0584

Resilience, Adverse Childhood Experiences, and Mental Health Symptoms in Youth with Juvenile Idiopathic Arthritis
Abstract Number: 1712

Resilience, Social Disadvantage and Disease Activity in Juvenile Idiopathic Arthritis
Abstract Number: 2831

Resolving the spatial molecular architecture of synovial inflammation in early RA using large-scale spatial transcriptomics.
Abstract Number: 0503

Respiratory infections and ILD progression account for more than 60% of deaths in RA-ILD: results from a multicenter cause-specific mortality analysis
Abstract Number: 2186

Respiratory Muscle Weakness in Systemic Sclerosis: Associations with Hand Grip Strength, Trunk Muscle Mass, and Total Muscle Mass.
Abstract Number: 2122

Response to Upadacitinib in New-Onset Versus Relapsing Giant Cell Arteritis: Two-Year Outcomes From the SELECT-GCA Phase 3 Trial
Abstract Number: 1287

Responsiveness of Patient-Reported Outcomes by Disease Trajectory in Systemic Lupus Erythematosus
Abstract Number: 0871

Retatrutide Once Weekly for the Treatment of Knee Osteoarthritis Pain and Obesity: Results From a 68-Week Phase 3 Randomized Clinical Trial
Abstract Number: 2792

Retreatment with Pegloticase – A Second Chance Worth Taking
Abstract Number: 2509

Return to Sports after Stress Fracture in Youth with Juvenile Idiopathic Arthritis: A Case-Control Study Evaluating Predictors of Recovery Time
Abstract Number: 2123

Reversible Cerebral Vasoconstriction Syndrome in Children: A Prevalent Mimic of Primary Angiitis of Central Nervous System Angiitis?
Abstract Number: 0527

Reversible Conversion Formulas Based on Partial Symmetric Linear Regression Models
Abstract Number: 2481

Rheum for Improvement: A Gamified, Case-Based Curriculum on Rheumatologic Testing
Abstract Number: 1761

Rheumatic and Musculoskeletal Disorders, Disability, and HIV-Related Factors Among People Aging with HIV: A Cross-Sectional Study
Abstract Number: 2922

Rheumatic Disease Flares, Management, and Cancer Outcomes with Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Abstract Number: 2681

Rheumatic Immune-Related Adverse Events In Patients Receiving Immune Checkpoint Inhibitors: Clinical Spectrum, Management, and Outcomes From a Single-Center Middle Eastern Registry
Abstract Number: 1458

Rheumatoid arthritis as accelerated immune aging: telomere length, immunosenescence and interstitial lung disease in a systematic review and meta-analysis
Abstract Number: 2449

Rheumatoid Arthritis Disease Modifying Treatments Before and After Lung Transplantation
Abstract Number: 0504

Rheumatoid Arthritis does not negatively impact overall survival in patients with Renal Cell Carcinoma treated with Immune Checkpoint Inhibitors- a real-world data study
Abstract Number: 1459

Rheumatoid Arthritis Is Independently Associated with Increased Respiratory Failure and In-Hospital Mortality Among Patients Hospitalized with Pneumonia: A National Inpatient Database Analysis
Abstract Number: 0505

Rheumatoid Arthritis Modifies the Association Between Continued Oral Bisphosphonate Therapy Beyond Three Years and Fracture Risk: A Multistate Retrospective Cohort Analysis of Bisphosphonate-Adherent U.S. Veterans
Abstract Number: 0100

Rheumatoid Arthritis Remains Associated with Lower Humoral but not Cellular Immune Response Beyond Primary COVID mRNA Vaccine Series in US Veterans
Abstract Number: 1460

Rheumatoid Factor (RF) Distribution in Patients with Rheumatoid Arthritis (RA): Results from the CorEvitas US RS Registry
Abstract Number: 0101

Rheumatoid Factors (RFs) Do Not Bind Fc‑Free Certolizumab Pegol, but Do Bind to Fc‑Containing Biological DMARDs, Leading to Immune Complex Formation Which Induces Cytokine Release from Human Peripheral Blood Mononuclear Cells (PBMC) In Vitro
Abstract Number: 0855

Rheumatologic Features of VEXAS Syndrome: A Multicenter French Cohort Study of 53 Patients
Abstract Number: 1807

Rheumatology Clinician Perspectives on Pillars of Lifestyle Medicine in Rheumatology
Abstract Number: 0856

Rheumatology Referral Characteristics and Outcomes in an Academic Clinic
Abstract Number: 0696

Riedel’s thyroiditis, the major manifestation of IgG4-related disease in the thyroid gland: A series of 16 patients
Abstract Number: 1883

Rilonacept Reduces Pericarditis Recurrence Risk, Hospitalizations, and ED Visits: Outcomes From the RESONANCE Patient Registry
Abstract Number: 2815

RIP3 promotes osteoclast differentiation through a non-canonical mechanism in subchondral bone during osteoarthritis progression
Abstract Number: 0823

Rising Age at Onset of Rheumatoid Arthritis in Japan and Machine Learning-Based Characterization of Late-Onset Disease: A Nationwide Registry Study
Abstract Number: 2731

Rising Burden, Unequal Costs: Country-Level Value of Lost Welfare Attributable to Rheumatoid Arthritis in 183 Countries, 1990-2023
Abstract Number: 2764

Rising Critical Illness Among Hospitalized Patients with Rheumatoid Arthritis: A Nationwide Analysis of 3.9 Million Hospitalizations, 2016-2022
Abstract Number: 0824

Rising Incidence and Rural-Urban Variation in Dermatomyositis: National Analysis Using Epic Cosmos
Abstract Number: 0857

Risk Characterization of Perioperative Acute Gout Flares: A Single-Center Case-Control Study
Abstract Number: 2307

Risk Factor Clusters Associated With Progression From Oligoarticular to Polyarticular Psoriatic Arthritis: Apremilast Treatment Effect in the FOREMOST Study
Abstract Number: 2510

Risk Factors and Outcomes of Seizures in Childhood-onset Lupus: A CARRA Registry Study
Abstract Number: 0586

Risk Factors Associated with Systemic JIA Lung Disease in a Large Multi-Center HLA-Typed Cohort
Abstract Number: 2884

Risk Factors for Interstitial Lung Disease in Patients with Rheumatoid Arthritis: Results from An International Study
Abstract Number: 0894

Risk Factors For Progression Of SI joint Structural Lesions On MRI In Early Axial SpA: 2-year Results From The SPondyloArthritis Caught Early Cohort
Abstract Number: 2409

Risk of Cancer Associated with bDMARDs and tsDMARDs in Patients with Rheumatoid Arthritis and a History of Cancer: Insights from the ARCA Registry
Abstract Number: 1634

Risk of Cirrhosis and Hepatic Complications in Patients with Hepatic Sarcoidosis Stratified by Transaminase Elevation: A Propensity Score-Matched Federated Health Network Analysis
Abstract Number: 1838

Risk of Gout Flares During the Transition to Maintenance Dialysis in Older Adults with Advanced Chronic Kidney Disease
Abstract Number: 1762

Risk of Hematologic Disorders in Patients with Behçet’s disease versus the General Population
Abstract Number: 2931

Risk of hypogammaglobulinemia and serious infections after rituximab treatment in patients with rheumatoid arthritis: A longitudinal retrospective cohort study
Abstract Number: 2308

Risk of Incident Enteropathic Spondyloarthritis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab Versus Anti-TNF Therapy: A Propensity-Matched Real-World Cohort Study
Abstract Number: 1763

Risk of incident Systemic Rheumatic Diseases among the General Population with Metabolic Syndrome: a Population-based Cohort Study
Abstract Number: 0825

Risk of Ischemic Heart Disease, Myocardial Infarction, and Related Mortality in Inflammatory Arthritis: A Nationwide Population-Based Cohort Study
Abstract Number: 0639

Risk of Localized Adverse Events Associated with Intra-Articular Therapies for the Treatment of Patients with Knee Osteoarthritis: A Systematic Review and Meta-analysis
Abstract Number: 0697

Risk of Major Adverse Cardiovascular Events in Patients with Psoriatic Arthritis and Concomitant Inflammatory Bowel Disease
Abstract Number: 0698

Risk of Non-Hodgkin Lymphoma and All-Cause Mortality in IgG4-Related Disease Versus Sjögren Disease: A Retrospective Cohort Study
Abstract Number: 1328

Risk of Psoriatic Arthritis in Patients with Psoriasis on Biologic Therapy
Abstract Number: 0826

Risk of Pulmonary Progression in Autoimmune Disease-associated Interstitial Lung Diseases
Abstract Number: 2410

Risk of Tuberculosis Reactivation in Patients Treated with Leflunomide: A Systematic Review and Meta-Analysis
Abstract Number: 2925

Risk of Venous Thromboembolism in Inflammatory Arthritis: Comparative Analysis of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
Abstract Number: 2959

Risk of Wound Complications Following Primary Total Joint Arthroplasty in Patients Receiving Anti-Rheumatic Medications: A Retrospective Cohort of 2,799 Patients
Abstract Number: 0827

Risks of Infections among New Users of Losartan vs. Amlodipine in Patients with Musculoskeletal Conditions: A Real-World Study of Medicare Beneficiaries
Abstract Number: 1181

Rituximab and Reduced Medrol Dosing in Systemic Sclerosis
Abstract Number: 1421

Rituximab for Inflammatory Ocular Disease in Rheumatoid Arthritis: A Systematic Review of Clinical Outcomes
Abstract Number: 1182

Rituximab in Systemic Sclerosis Refractory to csDMARDs – Preliminary Results of a Prospective Observational Monocentric Study over 36 Months
Abstract Number: 0205

Rituximab Maintenance Was Associated With Lower Relapse And Fewer Infection-Related Hospitalizations, and Lower Glucocorticoid Exposure in Elderly Japanese MPA-Dominant ANCA-Associated Vasculitis: A Single-Center Landmark Analysis
Abstract Number: 2145

Rituximab Plus Methotrexate Combination Therapy in Granulomatosis With Polyangiitis: Extended Multicenter Experience in 50 Patients
Abstract Number: 2090

Rituximab Treatment is Associated with Lower Prevalence of Lung B Cells and Lymphoid Aggregates but not Plasma Cells in SARD-ILD
Abstract Number: 0015

Ro+ Sjögren’s disease patients display selective enrichment of TCR V/J genes in the salivary gland with a distinguishing clonal profile
Abstract Number: 2091

ROCK1 and ROCK2 Inhibit the Acquisition of an Interferon Signature by Regulating the cGAS-STING Axis in B cells
Abstract Number: 0868

Rosnilimab Selectively Depletes Pathogenic T Cells and Downregulates Clinically Relevant Immune Pathways in Rheumatoid Arthritis: A Translational Analysis of Blood and Synovial Tissue from the Phase 2B Trial
Abstract Number: 1239

RTM-1000: A Brain-Penetrant Clinical Candidate cGAS Inhibitor with Cross-Species Activity, Efficacy in Trex1⁻/⁻ Mice, and Potential for CNS Autoimmune Indications
Abstract Number: 1422

Rural Disparities in Glucocorticoid Use Among Patients with Rheumatoid Arthritis
Abstract Number: 0506

Rural-Urban Disparities in Rheumatoid Arthritis Mortality in the United States
Abstract Number: 0906

Ruxolitinib-containing Rescue Therapy for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis: A Target Trial Emulation Study